Korro Bio, Inc.

Item 5. Other Information.

During the three months ended June 30, 2025, the following officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted contracts, instructions or written plans for the purchase or sale of our securities that were intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act (each, a “Rule 10b5-1 plan”): On June 11, 2025, Loïc Vincent, our Chief Scientific Officer, adopted a Rule 10b5-1 plan providing for the potential sale of up to 7,292 shares of our common stock issuable upon the exercise of stock options; this plan is scheduled to expire on May 21, 2027. On June 11, 2025, Jeffrey Cerio, our SVP, General Counsel and Corporate Secretary, adopted a Rule 10b5-1 plan providing for the potential sale of up to 6,000 shares of our common stock issuable upon the exercise of stock options; this plan is scheduled to expire on September 30, 2026. On June 27, 2025, Todd Chappell, our Chief Operating Officer, adopted a Rule 10b5-1 plan providing for the potential sale of up to 11,084 shares of our common stock issuable upon the exercise of stock options; this plan is scheduled to expire on June 30, 2026. On June 27, 2025, Ram Aiyar, our Chief Executive Officer & President, adopted a Rule 10b5-1 plan providing for the potential sale of up to 13,500 shares of our common stock issuable upon the exercise of stock options; this plan is scheduled to expire on June 30, 2026. During the three months ended June 30, 2025, none of our other officers or directors informed us that they adopted, modified orterminated a Rule 10b5-1 plan or a trading plan not intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.